Table 2.

SP effect on the incidence of clinical malaria during different periods in Ifakara and Manhiça

Outcome	Placebo			SP*			Protective efficacy	p
	Events	PYAR	Rate	Events	PYAR	Rate	(95% CI)
During 1 month after dose 1
Ifakara	8	21.71	0.37	1	22.21	0.05	87.8% (2.3;98.5)	0.012
Manhiça	13	47.48	0.27	1	49.97	0.02	92.7% (44.2;99.0)	< 0.001
Combined effect adjusted by study	21	69.19	0.30	2	72.18	0.03	90.9% (61.0;97.9)	< 0.001
During 1 month after dose 2
Ifakara	6	21.83	0.27	0	22.41	0.00	100% (.;100)	0.004
Manhiça	23	47.33	0.49	10	50.27	0.20	59.0% (13.8;80.5)	0.014
From 1 month after dose 2 until dose 3
Ifakara	32	100.08	0.32	16	106.04	0.15	52.8% (14.0;74.1)	0.011
Manhiça	92	169.09	0.54	85	183.36	0.46	14.7% (-14.6;36.5)	0.292
During 1 month after dose 3
Ifakara	14	21.51	0.65	2	22.32	0.09	86.2% (39.4;96.9)	0.001
Manhiça	32	46.94	0.68	16	49.82	0.32	52.7% (13.9;74.1)	0.012
During 6 months from 1 month after dose 3
Ifakara	51	112.56	0.45	37	120.90	0.31	32.2% (-3.5;55.6)	0.070
Manhiça	107	228.31	0.47	104	239.31	0.43	7.4% (-21.3;29.3)	0.578

*Sulphadoxine-pyrimethamine